XOMA Royalty (XOMA) Cash from Financing Activities (2010 - 2026)
XOMA Royalty (XOMA) reported Cash from Financing Activities of -$7.6 million for Q1 2026, down 10.82% on a YoY basis from -$8.6 million in Q1 2025, and up 28.52% sequentially from -$10.7 million in Q4 2025.
XOMA Royalty (XOMA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Cash from Financing Activities data on file, last reported at -$7.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 10.82% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$28.3 million (down 116.26% YoY), and the FY2025 full-year result was -$26.5 million, down 137.83% from the prior year.
- Cash from Financing Activities rose to -$7.6 million in Q1 2026, from -$10.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $124.5 million in Q4 2023 to a low of -$10.7 million in Q4 2025.
- A 5-year average of $4.8 million and a median of -$1.3 million in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 9517.1% in 2023 and slumped 902.72% in 2025, its largest moves.
- Tracing XOMA's Cash from Financing Activities over 5 years: stood at -$1.3 million in 2022, then jumped by 9517.1% to $124.5 million in 2023, then slumped by 100.86% to -$1.1 million in 2024, then tumbled by 902.72% to -$10.7 million in 2025, then grew by 28.52% to -$7.6 million in 2026.
- Business Quant data shows XOMA's Cash from Financing Activities at -$7.6 million in Q1 2026, -$10.7 million in Q4 2025, and -$3.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -7.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.64 Mn |
| Mar 31, 2026 | -7.64 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Mar 31, 2025 | -6.89 Mn |
| Mar 31, 2025 | -6.89 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Dec 31, 2023 | 124.49 Mn |
| Dec 31, 2023 | 124.49 Mn |
| Sep 30, 2023 | -1.37 Mn |
| Sep 30, 2023 | -1.37 Mn |